share_log

Kingworld Medicines Group's (HKG:1110) Promising Earnings May Rest On Soft Foundations

Kingworld Medicines Group's (HKG:1110) Promising Earnings May Rest On Soft Foundations

金威药业集团(HKG: 1110)的预期收益可能取决于软基础
Simply Wall St ·  04/29 18:37

Unsurprisingly, Kingworld Medicines Group Limited's (HKG:1110) stock price was strong on the back of its healthy earnings report. We did some analysis and think that investors are missing some details hidden beneath the profit numbers.

毫不奇怪,金华药业集团有限公司(HKG: 1110)的股价因其健康的收益报告而表现强劲。我们做了一些分析,认为投资者遗漏了一些隐藏在利润数字之下的细节。

earnings-and-revenue-history
SEHK:1110 Earnings and Revenue History April 29th 2024
SEHK: 1110 2024 年 4 月 29 日的收益和收入记录

How Do Unusual Items Influence Profit?

不寻常的物品如何影响利润?

For anyone who wants to understand Kingworld Medicines Group's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥12m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Kingworld Medicines Group doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

对于任何想了解金威药业集团在法定数字之外的利润的人来说,值得注意的是,在过去的十二个月中,从价值1200万元人民币的不寻常物品中获得了法定利润。我们不能否认更高的利润通常会让我们感到乐观,但如果利润是可持续的,我们更愿意这样做。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。考虑到这个名字,这并不奇怪。如果Kingworld Medicines Group认为这种捐款不会重演,那么在其他条件相同的情况下,我们预计其本年度的利润将下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Kingworld Medicines Group.

注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对金威药业集团的资产负债表分析。

Our Take On Kingworld Medicines Group's Profit Performance

我们对金威药业集团盈利表现的看法

Arguably, Kingworld Medicines Group's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Kingworld Medicines Group's statutory profits are better than its underlying earnings power. But the good news is that its EPS growth over the last three years has been very impressive. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Case in point: We've spotted 3 warning signs for Kingworld Medicines Group you should be mindful of and 1 of them shouldn't be ignored.

可以说,Kingworld Medicines Group的法定收益被提高利润的不寻常项目所扭曲。因此,我们认为金威药业集团的法定利润可能好于其基础盈利能力。但好消息是,其在过去三年中的每股收益增长非常令人印象深刻。归根结底,如果你想正确地了解公司,必须考虑的不仅仅是上述因素。请记住,在分析股票时,值得注意所涉及的风险。一个很好的例子:我们已经发现了金威药业集团的3个警告信号,你应该注意其中一个不容忽视。

Today we've zoomed in on a single data point to better understand the nature of Kingworld Medicines Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

今天,我们放大了单一数据点,以更好地了解金威药业集团利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多的事情需要发现。有些人认为高股本回报率是优质业务的好兆头。虽然可能需要你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发